Table 1.
Characteristics of patients with elevated (≥ 5) or non-elevated baseline NLR. Data are n (% of column total for overall or % of row total for NLR categories) unless otherwise indicated.
| Characteristic | Overall (n = 224) | NLR < 5 (n = 161) | NLR ≥ 5 (n = 63) | p value | |
|---|---|---|---|---|---|
| Age | Median (range) | 65.5 (24–94) | 64.7 (24–94) | 67.4 (28–91) | 0.113 |
| Sex | Male | 147 (66) | 103 (70) | 44 (30) | 0.438 |
| Female | 77 (34) | 58 (75) | 19 (25) | -- | |
| Pretreatment ECOG | 0 | 108 (48) | 93 (86) | 15 (14) | <0.001 |
| 1 | 87 (39) | 55 (63) | 32 (37) | -- | |
| 2+ | 19 (9) | 6 (32) | 13 (68) | -- | |
| Unknown | 10 (5) | 7 (70) | 3 (30) | -- | |
| Primary site | Cutaneous | 163 (73) | 123 (75) | 40 (25) | 0.112 |
| Mucosal | 27 (12) | 18 (67) | 9 (33) | -- | |
| Unknown primary | 34 (15) | 20 (59) | 14 (41) | -- | |
| Number of metastatic sites | 1 | 51 (23) | 46 (90) | 5 (10) | 0.001 |
| 2–3 | 116 (52) | 81 (70) | 35 (30) | -- | |
| 4+ | 57 (26) | 34 (60) | 23 (40) | -- | |
| AJCC M-Stage | M1a | 23 (10) | 19 (83) | 4 (17) | 0.012 |
| M1b | 39 (17) | 35 (90) | 4 (10) | -- | |
| M1c | 104 (46) | 69 (66) | 35 (34) | -- | |
| M1d | 58 (26) | 38 (66) | 20 (34) | -- | |
| BRAF Mutation | No | 134 (60) | 96 (72) | 38 (28) | 1.0 |
| Yes | 87 (39) | 63 (72) | 24 (28) | -- | |
| Unknown | 3 (1) | 2 (67) | 1 (33) | -- | |
| LDH | Normal | 119 (53) | 89 (75) | 30 (25) | 0.216 |
| Elevated | 53 (24) | 33 (62) | 20 (38) | -- | |
| Unknown | 52 (23) | 39 (75) | 13 (25) | -- | |
| Prior ipilimumab | No | 63 (27) | 46 (73) | 17 (27) | 0.870 |
| Yes | 161 (73) | 115 (71) | 46 (29) | -- | |
| Treatment | Nivolumab | 47 (21) | 33 (70) | 14 (30) | 0.855 |
| Pembrolizumab | 177 (79) | 128 (72) | 49 (28) | -- |